EBOS Group (EBO) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
19 Jan, 2026Opening remarks and agenda
Chair welcomed attendees in Auckland and online, outlined meeting format, and explained Q&A and voting procedures.
Quorum was declared, directors and executives introduced, and the agenda was set: year highlights, financial review, and formal business with five resolutions.
Chair Elizabeth Coutts and CEO John Cullity presented, followed by business items and meeting conclusion.
Financial performance review
FY 2024 revenue reached $13.2 billion, up 7.8% year-on-year; underlying EBITDA grew 7.3% to $624.3 million.
Net profit after tax rose 7.7% to $303.4 million; EPS increased 6.8% to 157.9 cents.
Healthcare and animal care segments delivered strong organic and acquisition-driven growth.
TerryWhite Chemmart network expanded to 600 stores; animal care EBITDA grew 13.2%.
ROCE aligned with 15% target; cost management improved operating efficiency.
Board and executive committee updates
Board renewal continued: Peter Williams retired, with Mark Bloom and Julie Tay appointed in the last two years.
Matt Muscio elected as director effective January 2025; search for an additional non-executive Australian director ongoing.
Chair signaled intention to retire after succession and knowledge transfer are complete.
Latest events from EBOS Group
- Revenue and EBITDA up 13% and 3.2%, with guidance reaffirmed and strong segment growth.EBO
H1 202625 Feb 2026 - FY25 saw strong revenue and EBITDA growth, but EPS fell due to contract loss and margin pressures.EBO
AGM 20253 Feb 2026 - Record FY24 growth and positive FY25 outlook despite Chemist Warehouse contract ending.EBO
H2 202423 Jan 2026 - Underlying revenue and EBITDA grew, guidance reaffirmed, and dividend maintained despite profit drop.EBO
H1 20256 Jan 2026 - 12% revenue and 7.5% EBITDA growth achieved, with 7% EBITDA uplift targeted for FY26.EBO
H2 202523 Nov 2025